

Intestinal Microbiota – A Modulator of the *Trypanosoma cruzi*-Vector-Host Triad

Isabella Teotônio¹, Nayra Dias¹, Luciana Hagström-Bex¹, Nadjar Nitz¹, Amanda Fortes Francisco² and Mariana Hecht^{1*}

¹ Interdisciplinary Laboratory of Biosciences, Faculty of Medicine, University of Brasilia, Brasilia, Federal District, Brazil.

² Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom.

*Correspondence:

Mrs. Isabella Márcia Soares Nogueira Teotônio

isabella.msn.rocha@gmail.com

Abstract. Chagas disease affects millions of people, and it is a major cause of death in Latin America. Prevention and development of an effective treatment for this infection can be favored by a more thorough understanding of *T. cruzi* interaction with the microbiome of vectors and hosts. Next-generation sequencing technology vastly broadened the knowledge about intestinal bacteria composition, showing that microbiota within each host (triatomines and mammals) is composed by high diversity of species, although few dominant phyla. This fact may represent an ecological balance that was acquired during the evolutionary process of the microbiome-host complex, and that serves to perpetuate this system. In this context, commensal microbiota is also essential to protect hosts, conferring them resistance to pathogens colonization. However, in some situations, the microbiota is not able to prevent infection but only modulate it. Here we will review the role of the microbiota on the parasite-vector-host triad with a focus on the kinetoplastida of medical importance *Trypanosoma cruzi*. Novel strategies to control Chagas disease based on intestinal microbiome will also be discussed.

Keywords: Intestinal microbiota, *Trypanosoma cruzi*, Vector, Host, Chagas disease.

Number of words: 2971

Number of figures: 2

1. Introduction

The intestinal ecosystem is an environment in which biological and biochemical interactions occur at various hierarchical levels, connecting microbial communities and their hosts. [^{1,2}] Studies of fecal samples revealed that the microbiota from a wholesome intestine is an intricately ecological community composed of trillions of

43 microorganisms, from viruses to unicellular eukaryotes.^[3] However, in this article, we
44 will use the term microbiota to refer only to the population of bacteria of an organism.

45 The intestinal microbiota is highly dynamic, it varies over time and is modulated
46 by environmental conditions (use of antibiotics, lifestyle, diet and hygiene preferences,
47 metabolic dysfunction, immunodeficiency and hyper immunity).^[4]The application of
48 new high-performance methodologies for analysis of bacterial species, such as the new
49 generation sequencing (NGS) of 16S rRNA, revolutionized the knowledge about the
50 intestinal microbiome. ^[5] It is now known that about 1000 bacterial species inhabit the
51 human adult intestine; however, the predominant genera are *Lactobacillus*,
52 *Bifidobacterium*, *Bacteroides*, *Eubacterium*, *Clostridium*, *Ruminococcus*,
53 *Peptostreptococcus*, and *Peptococcus*.^[5] Despite the large number of distinct species,
54 they belong to a relatively small number of phyla, especially Bacteroidetes and
55 Firmicutes. ^[6]

56 In healthy hosts, the presence of this microbiota contributes to the prevention of
57 pathogen colonization.^[7] Additionally, it has an important impact on various aspects of
58 the hosts physiology and metabolism; such as, protection of intestinal epithelium,
59 digestion of host nutrients, production of vitamins and hormones, and regulation of
60 immune responses, modulating the expression of immunological mediators and the
61 recruitment of certain cell populations.^[8,9]

62 Changes in microbiota composition usually have a direct effect on parasitic
63 infection, in part because parasites and bacteria metabolize substrates interactively and
64 secrete products that affect each other, interfering with the survival and physiology of
65 both. ^[10] Likewise, the microbial community constitution is an extremely important
66 factor for host immune responses: imbalance between the microbiota and the immune


67 system may alter the host's homeostasis and lead to greater disease susceptibility, and
68 therefore dictate the success of the intestinal pathogens.

69 Published data demonstrate that the intestinal microbiota usually has a deep
70 influence on the parasite-host relationship.^[11] It is well known that intestinal microbiota
71 composition is determinant for some parasites pathogenicity, as described for
72 *Entamoeba histolytica*,^[12] *Trichuris muris*,^[13] *Schistosoma mansoni*,^[14] *Eimeria*
73 *falciformis*,^[15] *Eimeria ovinoidalis*,^[16] *Ascaris lumbricoides*,^[17] and *Giardia lamblia*.
74 ^[18]

75 On the other hand, this microbiota can reduce the damages of other infectious
76 agents, such as *Cryptococcus neoformans*,^[19] *Strongyloides venezuelensis*,^[20] and
77 almost all enteropathogenic bacteria (*Clostridium difficile*, *Clostridium perfringens*,
78 *Escherichia coli*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Shigella xexneri*
79 and *Vibrio cholerae*).^[21, 22, 23] In few reported cases - *Raillietina cestitillus*,^[24] *Isopora*
80 *suis*,^[25] and *Trichuris trichiura* ^[17]- the microbiota composition appear not to influence
81 the outcome of the disease.

82 *T. cruzi* is the etiological agent of Chagas disease, the most important parasitic
83 disease in the Americas, affecting approximately 6 to 8 million people and causing
84 around 12,000 deaths per year. ^[26] Little is known about the modulation of *T. cruzi*
85 infections by the intestinal microbiota, in insects or vertebrate hosts. Approximately
86 30% of infected individuals will develop cardiac, digestive or neurological changes
87 during the chronic phase. Chagas disease pathogenesis has not been fully elucidated,
88 and different theories try to explain it, such as parasite persistence and
89 autoimmunity.^[27] This fact contributes to the difficulty in developing an effective
90 treatment. In this review, we will summarize the current knowledge on microbiome of

91 *T. cruzi* invertebrate and vertebrate hosts, highlighting new approaches and research
 92 gaps in this field (Figure 1).



93

94 **Figure 1. Multi-effects of the intestinal microbiota on the vector-parasite-host**
 95 **triad.** In healthy, non-infected, vectors and hosts, the resident microbiota will play an
 96 important role in the maintenance of homeostasis (eubiosis). During *T. cruzi* infection,
 97 the parasite and bacteria metabolize substrates interactively and secrete products that
 98 affect each other and interfere in the survival and physiology of the host (dysbiosis).

99

100 2. Gut microbiota in parasite-vector interface

101 Hemiptera insects began to inhabit our planet about 400 million years ago, being
 102 favored by the emergence of vascular plants, whose phloem served as their food source.
 103 Throughout the evolutionary process, adaptations of the oral apparatus of these
 104 arthropods allowed the acquisition of new feeding habits, such as hematophagy. [²⁸,
 105 ²⁹]Triatomines (Hemiptera: Reduviidae), popularly known as kissing bugs, are life-long
 106 obligatorily hematophagous arthropods which feed on various animals, mainly
 107 mammals. During hematophagy, several microorganisms can reach triatomines
 108 alimentary tract and begin its colonization.

109 In recent years, triatomines microbiota has been evaluated by NGS, showing that
110 the ecological diversity of its microbiome is low but dynamic, changing according to
111 genera and gender, development stages origin, and blood sources.^[30, 31, 32] The
112 assessment of *T. brasiliensis* and *T. pseudomaculata* microbiome by denaturing gradient
113 gel bands sequencing revealed their microbiota was mostly composed by Proteo- and
114 Actinobacteria; being *Serratia* the predominant genus. ^[33]Analyses of the 16S rRNA
115 gene of the intestinal microbiota of *Triatoma maculata* and *Rhodnius pallescens*
116 captured in the same locality of Colombia, showed the distinct composition of bacteria
117 community. In *R. pallescens*, *Williamsia* and *Kocuria* (orders Corynebacteriales and
118 Actinomycetales, respectively) were the most prevalent genera, while in *T. maculate*,
119 *Dietzia*, *Aeromonas* and *Pelomonas* (orders Actinomycetales, Aeromonadales and
120 Burkholderiales, respectively) were predominant.^[30]Another study confirmed that 70%
121 of *Triatoma diminiata* microbiome was composed by bacteria from orders Bacillales,
122 Actinomycetales, Enterobacteriales and Burkholderiales. However, the predominating
123 bacteria in bugs fed on dogs was Burkholderiales, in those fed on humans was
124 Bacillales, and for those fed on porcupine was Enterobacteriales. ^[31]Interestingly,
125 Rodríguez-Ruano et al., ^[34] showed that the microbiome composition is particularly
126 determined by host species, receiving less influence of locality and environment.

127 Following a blood meal, kissing bugs can also ingest the protozoa *T. cruzi*. Once
128 inside the insect gut, *T. cruzi* have to invade surrounding tissues of the vector and
129 transform to epimastigote forms and later, in infective metacyclic forms, which are
130 eliminated with excreta and can achieve the host bloodstream through the bite site.
131 During this journey, *T. cruzi* and the resident microbiota maintain an intimate
132 interaction looking for a balance for the establishment of both.

133 Independently of gut microbiota composition, most of *T. cruzi* is destructed in
134 the first hours of vector infection. [35]After that, parasite-microbiota interaction is
135 essential to control *T. cruzi* amount. *In vitro* experiments showed that bacterial clusters
136 can adhere to *T. cruzi* surface through D-mannose recognizing fimbriae and lead to
137 parasite lysis. [35]Furthermore, a control of parasite replication is also orchestrated by
138 the local bacteria.[36]Thus, to provide continuity to its life cycle in the digestive tract of
139 triatomines and increase their chances of reaching a new host, *T. cruzi* needs to
140 overcome the microbiota trypanolytic activity. The interaction between parasite and
141 microbiota could vary among different vectors. As an example, *T. cruzi* Dm28c strain
142 when stimulated induce antibacterial activities in *Rhodnius prolixus*, resulting in fewer
143 bacteria and higher parasitemia. However, the *T. cruzi* Y strain is not able to produce
144 the same effects, being inefficient in the establishment of the infection in the vector.[37]

145 Vectors infected with *T. cruzi* synthesize antimicrobial peptides, such as
146 defensins and prolixicin, to control the expansion of the new invader, in a strain-
147 dependent manner. [38]These bioactive molecules may also affect the resident
148 microbiota richness,[34]and consequently, benefit or impair parasite survival. For
149 example, the use of a selective inhibitor of NF- κ b in *R. prolixus* modulated the gene
150 expression of defensins, increasing the microbiota and reducing *T. cruzi* population.
151 [39]Furthermore, the knockdown of the antimicrobial product from *Triatoma infestans*
152 midgut (TiAP) increased by 600 times the amount of gut bacteria and, consequently,
153 reduced the number of *T. cruzi* epimastigotes.[40]So, TiAP controls microbiota growth,
154 contributing to *T. cruzi* establishment in the vector. Similarly, a Kazal-type inhibitor
155 from the midgut of *R. prolixus* (RpTI) is involved in microbiota regulation and its
156 silencing with RNA interference technology resulted in higher bacterial loads.[41]In
157 contrast, Díaz et al.[42]reported that triatomines challenged with *T. cruzi* have their

158 microbiome altered in a species-specific manner; harboring a more diverse bacterial
159 community than the negative controls. The significance of this increase in diversity
160 must be better investigated.

161

162 **3. Gastrointestinal microbiota in the parasite-mammal interface**

163 Novel bioluminescence imaging systems have evidenced the persistence of *T.*
164 *cruzi* infection in the GIT (gastrointestinal tract) during the acute and chronic Chagas
165 disease.^[43, 44]The persistence of *T. cruzi* in the gut could contribute to the development
166 of GIT disorders, notably megacolon and/or megaesophagus, resulting in altered
167 peristaltic movements, dysphagia and pain. It is believed that the chronic
168 gastrointestinal symptoms of Chagas disease are a consequence of the destruction of the
169 myenteric neurons by the parasite. ^[45]Furthermore, continuous migration of *T. cruzi*
170 from the GIT to other organs such as the heart has been suggested, indicating that the
171 intermittent traffic of parasites can be involved in chronic Chagas cardiomyopathy.^{[44,}
172 ^{46]}

173 In the gut, *T. cruzi* may interact with thousands of commensal bacteria, but little
174 is known about this ecological relationship. Apparently, an indirect contact should occur
175 between parasite-bacteria, since *T. cruzi* is preferentially found in the muscularis
176 externae of GIT.^[47]The impact of this protozoa on microbiota profile and metabolome
177 were characterized in an immunocompetent murine model, ^[48] in which *T. cruzi*
178 disrupted fecal microbiome and caused biochemical alterations in a synchronized
179 manner. For example, variations in linoleic acid metabolism could be observed.⁴⁸
180 Linoleic acid metabolism has been associated with an important immune-modulating
181 response, affecting T cell recruitment and cytokines production in the colon, ^[49] which
182 could favor *T. cruzi* persistence.

183 Researches on germ-free mice infected with *T. cruzi* have been performed to
184 characterize immunoregulation and clinical evolution of Chagas disease in this
185 experimental model. Silva et al., [50] showed that the lack of the natural microbiome
186 negatively influenced parasitemia intensity, mortality rate, spleen size, and cardiac
187 damage. However, the same findings were not obtained by Duarte et al., [51] in whose
188 study the infection outcome did not alter significantly between control and germ-free
189 mice, despite a higher production of inflammatory cytokines in the first group.

190 The role of specific species of bacteria on Chagas disease immunomodulation
191 was also evaluated in germ-free mice. [52] Mono-association of *T. cruzi* with *E. coli*, *E.*
192 *faecalis*, *B. vulgatus* or *Peptostreptococcus* sp produced a Th1 immune response, higher
193 levels of IgGs and increased survival rate. Interestingly, these tested bacteria are
194 predominant in the indigenous microbiota, but there is no evidence that this population
195 group is more resistant to the development of Chagas disease clinical manifestations. [53]
196] In this respect, characterization of the microbiome in coprolites and colon of a chagasic
197 pre-Columbian Andean mummy revealed that paleofeces were constituted
198 predominantly by Firmicutes, with *Clostridium* spp. and *Turicibacter* spp. representing
199 the most abundant bacterial genera. [54]

200 Since gut microbiome depends on intestinal health, it is expected its impairment
201 during Chagas disease, regardless of ancestry. Quantitative and qualitative analysis of
202 the microbiota in chagasic megaesophagus and health esophagus showed a more
203 elevated bacterial concentration and variability in chagasic patients, with a
204 predominance of the aerobic gram-positive bacteria *Streptococcus* sp and the anaerobic
205 *Veillonella*. [55] In the proximal jejunum of patients with megacolon, it was observed an
206 overgrowth of facultative and strict anaerobes microorganisms, which returns to
207 normality after surgical treatment. [56]

208 Dysbiosis in Chagas disease may also be associated with the emergence of
209 secondary diseases. The proliferation of certain bacteria in the esophageal lumen can
210 cause pulmonary infections, dysplasia of the esophageal mucosa and
211 cancer.^[55] Individuals with a more advanced stage of esophageal dilation have elevated
212 concentrations of *Staphylococcus* sp, *Corynebacterium* sp, *Peptostreptococcus* sp and
213 *Veillonella* sp, bacteria that are capable of reducing nitrate into nitrites, which have been
214 associated with the formation of proven esophageal carcinogens nitrosamines. ^[57, 58]

215

216 **4. Novel approaches based on intestinal microbiota to control chagas disease**

217 In triatomines, obligate bacterial symbionts are essential to obtain some nutrients
218 from the blood-diet, without which several aspects of insect physiology would be
219 compromised, notably its development. ^[59, 60] It is noteworthy to note that the
220 availability of nutrients affects the vector, the *T. cruzi* population density and the
221 number of metacyclic tripomastigotes in the rectum. ^[61] Therefore, bacterial
222 communities in the insect gut are essential for *T. cruzi* survival.^[62] Interestingly, new
223 methodologies are being developed to facilitate the characterization of triatomines gut
224 ecosystem: RADseq-based analysis was used to disclose mixed DNA from vectors
225 abdomens, enabling the determination of *T. cruzi* DTUs, microbial diversity, and blood
226 meal source. ^[63]


227 In this sense, it is quite plausible to think about novel strategies of *T. cruzi*
228 transmission blocking and vector control based on its microbiota (Figure 2), since the
229 traditional strategies seem to be ineffective, such as the use of insecticides. ^[64] Studies
230 employing antibiotic treatment, specific antibodies or rearing gnotobiotic lines has
231 brought important information about the role of intestinal bacteria on
232 parasites.^[65] Triatomine engineering aiming antimicrobial peptides reduction results in

233 increased bacterial load in the midgut and decreased *T. cruzi* parasitemia, influencing
234 vector competence. [40] It is noted that production of genetically-modified vectors that
235 interferes in microbial colonization is an advantageous strategy because it can be
236 applied to all species of triatomines and impairs *T. cruzi* survival. Intestinal microbiota
237 can also be modified by RNA interference-based technologies to control vectors: *E. coli*
238 expressing specific dsRNAs for *Rhodnius prolixus* heme-binding protein and catalase
239 affected mortality, molting and oviposition rates.[66] Other examples of promising
240 alternatives to control vector infection are the use of bacteria with trypanocidal activity,
241 such as *Serratia*, a commensal of triatomine guts that deregulates *T. cruzi* mitochondrial
242 activity.[67] and the treatment of *R. prolixus* with physalin B, a natural secosteroid that
243 promotes an increase in gut bacterial microbiota and significantly decreases the number
244 of *T. cruzi*. [68]

245 In mammals, commensal microbes interact with parasites that cohabitate and
246 change the progression of the infection. Recent discoveries, [44; 43] show the intestine as
247 a preferential site of *T. cruzi*, where local bacteria can act directly on the parasite and
248 determine its infectivity. Furthermore, infection can also be modulated at distance. In
249 both cases, the mutualism developed between parasites and microbiota seems to be
250 associated with subclinical manifestations. [69] Therefore, the administration of
251 prebiotics and probiotics to replace the resident microbiota can be promising, since the
252 newly introduced bacteria will compete with the parasites for nutrients and space as
253 well as stimulate the host's immune system to react against infection.[70] Identification
254 of which prebiotics/probiotics can boost protective immune responses can contribute to
255 the success of future treatments. In this respect, oral and intraperitoneal inoculation of *L.*
256 *casei* in NIH mice resulted in reduction of circulating parasites.[71]

257 Associated to this, specific diets may contribute to the growth of the microbiota
258 species of interest that diminish the virulence and survival of the parasites.^[69] High fat
259 diet and protein deficiency seems to increase parasitemia and leucocyte infiltration in
260 cardiac tissue. ^[72, 73] Such aspects become more evident when analyzed in germ-free
261 mice. Cintra et al. ^[74] showed that protein deficiency resulted in a more severe Chagas
262 disease in germ-free mice than the controls. Santos et al. ^[75] observed that the effect of a
263 deficient fatty acid diet on a germ-free *T. cruzi*-infected model resulted in a larger
264 amount of tripomastogotes per ml of blood and a lower survival rate.

265 New insights about which mechanisms are involved in parasite-microbiota
266 interaction are also needed. For example, the role of inflammasome should be better
267 elucidated, since its activation controls microbial dysbiosis, protecting the organisms
268 from autoinflammatory responses. However, parasites can reduce inflammasome
269 activation, promoting dysbiosis.^[76]



270

271 **Figure 2. Challenges to consolidate the knowledge about the role of the intestinal**
 272 **microbiota on the vector-parasite-host triad.** Gaps in research need to be fulfilled to
 273 determine the real importance of the intestinal microbiota on *T. cruzi* infection. Novel
 274 approaches are essential to elucidate crucial issues.

275

276 5. Conclusions

277 Reports on parasites and microbiota interaction have become extremely common
 278 because of next-generation sequencing technology. However, a bias may have been
 279 created because of the possibility of lack of DNA sequencing from less abundant, but of
 280 pathological importance, bacteria populations. Furthermore, expanding knowledge
 281 about Archae diversity [77] and its interaction with the microbiota can evidence new
 282 aspects of the complex GIT ecosystem. Also, the inclusion of virus, fungi and,
 283 eukaryotes should be considered in the next studies.

284 Importantly, some results may be valid for certain ecological conditions, but not
 285 to others. So, field-based research can bring to light information that could not be

286 obtained in controlled lab-models. Another research line that should be further explored
287 in order to address how intestinal bacteria are acquired and maintained in hosts and
288 which combination of bacteria could be required to protect against *T. cruzi* infection.
289 [⁷⁸]Understanding the mechanisms that interfere in infection progression is essential.
290 Experiments with *T. cruzi* infected animals treated with antibiotics and recolonized with
291 specific bacteria can provide important information of how these microorganisms
292 modulate the infection. Gene exchange among microbiome-parasite-hosts is a
293 possibility that should be considered in this intimate relationship.

294 **Disclosure**

295 There is no conflict of interest to be discussed.

296 **References**

- 297
298 1. Bradford MA, Fierer N. The Biogeography of microbial communities and ecosystem
299 processes: implications for soil and ecosystem models. In: Soil Ecology and Ecosystem
300 Services. Oxford, UK: Oxford University Press, p. 189-200, 2012.
301
302 2. Candela M, Biagi E, Turrone S, et al. Mechanisms involved in the intestinal
303 interaction between host and bifidobacteria. *Microb Ecol Health Dis*, v. 20 p.189-192,
304 2008.
305
306 3. Partida-Rodríguez, O., Serrano-Vázquez, A., Nieves-Ramírez, M. E., Moran, P.,
307 Rojas, L., Portillo, T., Ximenez, C. Human Intestinal Microbiota: Interaction Between
308 Parasites and the Host Immune Response. *Archives of Medical Research*, v. 48, n.8,
309 690–700, 2017.
310
311 4. Sommer F, Backhed F. The gut microbiota-masters of host development and
312 physiology. *Nat Rev Microbiol*, v.11, p.227-38, 2013.
313
314 5. Kim T, Mundt E. Metagenomic analysis of intestinal microbiomes in chickens.
315 *Methods Mol Biol*, v.733, p.185-194, 2011.
316
317 6. Ismail NA, Ragab SH, ElBaky AA, et al. Frequency of Firmicutes and Bacteroidetes
318 in gut microbiota in obese and normal weight Egyptian children and adults. *Arch Med*
319 *Sci.*, v. 3 p. 501-507, 2011.
320
321 7. Schuijt, T. J., Lankelma, J. M., Scicluna, B. P., De Sousa E Melo, F., Roelofs, J. J. T.
322 H., De Boer, J. D. Wiersinga, W. J. The gut microbiota plays a protective role in the
323 host defence against pneumococcal pneumonia. *Gut*, v.65, n. 4, p. 575–583, 2016.

- 324
325 8. Sjögren Y. M., Tomicic S., Lundberg A., et al. Influence of early gut microbiota on
326 the maturation of childhood mucosal and systemic immune responses. *Clin Exp Allergy*,
327 v.39, p. 1842-1851, 2009.
328
- 329 9. Caballero S, PamerEG. Microbiota-mediated inflammation and antimicrobial defense
330 in the intestine. *Annu Rev Immunol*,v. 33 p. 227-256. 2015.
331
- 332 10. Berrilli, F., Cave, D. Di, Cavallero, S., & Amelio, S. D. Interactions between
333 parasites and microbial communities in the human gut. *Front Cell Infect Microbiol.*, v.
334 2, p. 1–6, 2012.
335
- 336 11. Bär A.K.; Phukan N.; Pinheiro J.; Simoes-Barbosa A. The interplay of host
337 microbiota and parasitic protozoans at mucosal interfaces: implications for the outcomes
338 of infections and diseases. *PLoS Negl. Trop. Dis.* V.9, p.e0004176, 2015.
339
- 340 12. Burgess S. L., Petri W. A. Jr. The Intestinal Bacterial Microbiome and *E. histolytica*
341 Infection. *Curr Trop Med Rep.* v. 3, p.71-74, 2016.
- 342 13. Leung J. M., Budischak S. A., Chung TH., Hansen C., Bowcutt R., Neill R.,
343 Shellman M., Loke P., Graham AL. Rapid environmental effects on gut nematode
344 susceptibility in rewilded mice. *PLoS Biol.* V. 16, n.3, p. e2004108, 2018b.
- 345
- 346 14. Jenkins T. P., Peachey L. E., Ajami N. J., MacDonald A. S., Hsieh M. H., Brindley
347 P. J., Cantacessi C., Rinaldi G. *Schistosoma mansoni* infection is associated with
348 quantitative and qualitative modifications of the mammalian intestinal microbiota. *Sci*
349 *Rep.* v.8, n.1, p.12072, 2018.
350
- 351 15. Owen, D. *Eimeria falciformis* (Eimer, 1870) in speciWc pathogen free and
352 gnotobiotic mice. *Parasitology*, v. 71, p. 293–303, 1975.
353
- 354 16. Przyjalkowski, Z., Wescott, R.B. *Trichinella spiralis*: establish- ment in gnotobiotic
355 mice aVected by *Bacillus mesentericus*, *Bacillus subtilis* and *Pseudomonas aeruginosa*.
356 *Experimental Parasitology*, v. 25, p. 8–12, 1969.
357
- 358 17. Cooper P., Walker A. W., Reyes J., Chico M, S. S. J., Vaca M., Parkhill J. Patent
359 human infections with the whipworm, *Trichuris trichiura*, are not associated with
360 alterations in the faecal microbiota. *PLoS One.* V. 8, n. 10, 2013.
- 361
- 362 18. Torres, M.F., Uetanabaro, A.P.T., Costa, A.F., Alves, C.A., Farias, L.M., Bambirra,
363 E.A., Penna, F.J., Vieira, E.C., Nicoli, J.R. Influence of bacteria from the duodenal
364 microbiota of patients with symptomatic giardiasis on the pathogenicity of *Giardia*
365 *duodenalis* in gnotoxenic mice. *Journal of Medical Microbiology*, v.49, p.209–215,
366 2000.
367
- 368 19. Salkowski, C.A., Bartizal, K.F., Balish, M.J., Balish, E. Colonization and
369 pathogenesis of *Cryptococcus neoformans* in gnotobiotic mice. *Infection and Immunity*,
370 v. 55, 2000–2005, 1987.
371

- 372 20. Martins, W.A., Melo, A.L., Nicoli, J.R., Cara, D.C., Carvalho, M.A.R., Lana, M.A.,
373 Vieira, E.C., Farias, L.M. A method of decon- taminating *Strongyloides venezuelensis*
374 larvae for the study of strongyloidiasis in germfree and conventional mice. *Journal of*
375 *Medical Microbiology*, v. 49, p. 387–390, 2000.
- 376
377 21. Wilson, K.H. Ecological concepts in the control of pathogens. In: Roth, J.A. (Ed.),
378 *Virulence Mechanisms of Bacterial Pathogens*. American Society for Microbiology,
379 Washington, p. 245–256, 1995.
- 380
381 22. Muñoz-Quezada S., Bermudez-Brito M., Chenoll E., Genovés S., Gomez-Llorente
382 C., Plaza-Diaz J., Matencio E., Bernal M.J., Romero F., Ramón D., Gil A. Competitive
383 inhibition of three novel bacteria isolated from faeces of breast milk-fed infants against
384 selected enteropathogens. *Br J Nutr*. v. 109, p. S63-9, 2013.
- 385
386 23. Cui X., Shi Y., Gu S., Yan X., Chen H., Ge J. Antibacterial and Antibiofilm
387 Activity of Lactic Acid Bacteria Isolated from Traditional Artisanal Milk Cheese from
388 Northeast China Against Enteropathogenic Bacteria. *Probiotics Antimicrob Proteins*.
389 doi: 10.1007/s12602-017-9364-9, 2017.
- 390
391 24. Reid, W.M., Botero, H. Growth of the cestode *Raillietina cesticillus* in bacteria-free
392 chickens. *Experimental Parasitology*, v. 21, p.149–153, 1967.
- 393
394
395 25. Harleman, J.H., Meyer, R.C. Life cycle of *Isopora suis* in gnoto- biotic and
396 conventional piglets. *Veterinary Parasitology*, v. 17, p. 27–39, 1984.
- 397
398 26. WHO/PAHO | Chagas disease (American trypanosomiasis), WHO. (2018).
399 [http://www.who.int/chagas/disease/en//https://www.paho.org/hq/index.php?option=com](http://www.who.int/chagas/disease/en//https://www.paho.org/hq/index.php?option=com_topics&view=article&id=10&Itemid=40743&lang=en)
400 [_topics&view=article&id=10&Itemid=40743&lang=en](http://www.who.int/chagas/disease/en//https://www.paho.org/hq/index.php?option=com_topics&view=article&id=10&Itemid=40743&lang=en) (accessed September 12, 2018).
- 401
402
403 27. Teixeira, A. R. L. et al. Pathogenesis of chagas’ disease: Parasite persistence and
404 autoimmunity. *Clinical Microbiology Reviews*, v. 24, n. 3, p. 592–630, 2011.
- 405
406 28. Wilf P., Labandeira C. C. Response of plant-insect associations to paleocene-eocene
407 warming. *Science*.v. 284, n.5423, p.2153-6, 1999.
- 408
409 29. Gaunt M. W., Miles M. A. An insect molecular clock dates the origin of the insects
410 and accords with palaeontological and biogeographic landmarks. *Mol Biol Evol*.v.19,n.
411 5, p. 748-61, 2002.
- 412
413 30. Montoya-Porras, L. M. et al. 16S rRNA gene amplicon sequencing reveals
414 dominance of Actinobacteria in *Rhodnius pallescens* compared to *Triatoma maculata*
415 midgut microbiota in natural populations of vector insects from Colombia. *Acta*
416 *Tropica*, v. 178, p. 327–332, 2018.
- 417
418 31. Dumonteil, E. et al. Detailed ecological associations of triatomines revealed by
419 metabarcoding and next-generation sequencing: implications for triatomine behavior

- 420 and *Trypanosoma cruzi* transmission cycles. *Scientific Reports*, v. 8, n. 1, p. 4140,
421 2018.
- 422
- 423 32. Oliveira, J. L. et al. Field-collected *Triatoma sordida* from central Brazil display
424 high microbiota diversity that varies with regard to developmental stage and intestinal
425 segmentation. *PLOS Neglected Tropical Diseases*, v. 12, n. 8, p. 1-20, 2018.
- 426
- 427 33. Gumiel M., da Mota F.F., Rizzo V. S., Sarquis O., de Castro D.P., Lima M.M.,
428 Garcia E.S., Carels N., Azambuja P. Characterization of the microbiota in the guts of
429 *Triatoma brasiliensis* and *Triatoma pseudomaculata* infected by *Trypanosoma cruzi* in
430 natural conditions using culture independent methods. *Parasit Vectors*. v. 8:245, 2015.
- 431
- 432 34. Rodríguez-Ruano, S. M. et al. Microbiomes of North American triatominae: The
433 grounds for Chagas disease epidemiology. *Frontiers in Microbiology*, v. 9, p. 1–11,
434 2018.
- 435
- 436 35. Castro, D. P. et al. *Trypanosoma cruzi*: Ultrastructural studies of adhesion, lysis and
437 biofilm formation by *Serratia marcescens*. *Experimental Parasitology*, v. 117, n. 2, p.
438 201–207, 2007.
- 439
- 440
- 441 36. Dias, F. DE A. et al. Monitoring of the Parasite Load in the Digestive Tract of
442 *Rhodnius prolixus* by Combined qPCR Analysis and Imaging Techniques Provides
443 New Insights into the Trypanosome Life Cycle. *PLoS Neglected Tropical Diseases*, v.
444 9, n. 10, p. 1–23, 2015.
- 445
- 446 37. Castro, D. P. et al. *Trypanosoma cruzi* immune response modulation decreases
447 microbiota in *rhodnius prolixus* gut and is crucial for parasite survival and development.
448 *PLoS ONE*, v. 7, n. 5, p. 3–10, 2012 a.
- 449
- 450
- 451 38. Vieira, C. et al. Impact of *Trypanosoma cruzi* on antimicrobial peptide gene
452 expression and activity in the fat body and midgut of *Rhodnius prolixus*. *Parasites &*
453 *Vectors*, v. 9, n. 1, p. 119, 2016.
- 454
- 455
- 456 39. Vieira C. S., Moreira O. C., Batista K. K. S., Ratcliffe N.A., Castro D. P., Azambuja
457 P. The NF- κ B Inhibitor, IMD-0354, Affects Immune Gene Expression, Bacterial
458 Microbiota and *Trypanosoma cruzi* Infection in *Rhodnius prolixus* Midgut. *Front*
459 *Physiol*. v. 9:1189, 2018.
- 460
- 461 40. Buarque, D. S. et al. A new antimicrobial protein from the anterior midgut of
462 *Triatoma infestans* mediates *Trypanosoma cruzi* establishment by controlling the
463 microbiota. *Biochimie*, v. 123, p. 138–143, 2016.
- 464
- 465 41. Soares, T. S. et al. A Kazal-type inhibitor is modulated by *Trypanosoma cruzi* to
466 control microbiota inside the anterior midgut of *Rhodnius prolixus*. *Biochimie*, v. 112,
467 p. 41–48, 2015.
- 468
- 469 42. Díaz, S. et al. Triatomine bugs, their microbiota and *Trypanosoma cruzi*:

- 470 Asymmetric responses of bacteria to an infected blood meal. *Parasites and Vectors*, v. 9,
471 n. 1, p. 1–11, 2016.
- 472
- 473 43. Silberstein, E., Serna, C., Fragoso, S. P., Nagarkatti, R., & Debrabant, A.. A novel
474 nanoluciferase-based system to monitor *Trypanosoma cruzi* infection in mice by
475 bioluminescence imaging. *PLoS ONE*, v.13, n. 4, p.1–21, 2018.
- 476
- 477
- 478 44. Lewis, M. D. et al. Bioluminescence imaging of chronic *Trypanosoma cruzi*
479 infections reveals tissue-specific parasite dynamics and heart disease in the absence of
480 locally persistent infection. *Cellular Microbiology*, v. 16, n. May, p. 1285–1300, 2014.
- 481
- 482 45. Jabari, S. et al. Chagasic megacolon: Enteric neurons and related structures.
483 *Histochemistry and Cell Biology*, v. 142, n. 3, p. 235–244, 2014.
- 484
- 485 46. Lewis, M. D.; KELLY, J. M. Putting Infection Dynamics at the Heart of Chagas
486 Disease. *Trends in Parasitology*, v. 32, n. 11, p. 899–911, 2016.
- 487
- 488 47. Costa F. C., Francisco A. F., Jayawardhana S., Calderano S. G., Lewis M. D., Olmo
489 F., Beneke T., Gluenz E., Sunter J., Dean S., Kelly J. M., Taylor M. C. Expanding the
490 toolbox for *Trypanosoma cruzi*: A parasite line incorporating a bioluminescence-
491 fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo
492 localisation and phenotyping. *PLoS Negl Trop Dis*. v. 2, e0006388, 2018.
- 493
- 494 48. Mccall, L. I. et al. Experimental Chagas disease-induced perturbations of the fecal
495 microbiome and metabolome. *PLoS Neglected Tropical Diseases*, v. 12, n. 3, p. 1–15,
496 2018.
- 497
- 498
- 499 49. Bassaganya-Riera J., Hontecillas R., Beitz D.C. Colonic anti-inflammatory
500 mechanisms of conjugated linoleic acid. *Clin Nutr*. v.21, n. 6, p.451-9, 2002.
- 501
- 502
- 503 50. Silva M. E., Evangelista E. A., Nicoli J. R., Bambirra E. A., Vieira E. C. American
504 trypanosomiasis (Chagas' disease) in conventional and germfree rats and mice. *Rev Inst*
505 *Med Trop Sao Paulo*. v. 29, n. 5, p. 284-8, 1987.
- 506
- 507 51. Duarte R., Silva A. M., Vieira L. Q., Afonso L. C., Nicoli J. R. Influence of normal
508 microbiota on some aspects of the immune response during experimental infection with
509 *Trypanosoma cruzi* in mice. *J Med Microbiol*. v. 53, n.8, p.741-8, 2004.
- 510
- 511
- 512 52. Duarte, R. et al. *Trypanosoma cruzi*: Influence of predominant bacteria from
513 indigenous digestive microbiota on experimental infection in mice. *Experimental*
514 *Parasitology*, v. 111, n. 2, p. 87–96, 2005.
- 515
- 516 53. Lima-Costa, M. F. et al. Genomic African and Native American Ancestry and
517 Chagas Disease: The Bambui (Brazil) Epigen Cohort Study of Aging. *PLoS Neglected*
518 *Tropical Diseases*, v. 10, n. 5, p. 1–14, 2016.

- 519
520
521 54. Santiago-Rodriguez, T. M. et al. Gut microbiome of an 11th-century A.D. Pre-
522 Columbian andean mummy. PLoS ONE, v. 10, n. 9, p. 1–23, 2015.
523
524
525 55. Pajecki D., Zilberstein B., dos Santos M. A., Ubriaco J. A., Quintanilha A. G.,
526 Ceconello I., Gama-Rodrigues J. Megaesophagus microbiota: a qualitative and
527 quantitative analysis. J Gastrointest Surg.v.6,n. 5, p.723-9, 2002.
528
529
530 56. Guimarães Quintanilha AG, Azevedo dos Santos MA, Avila-Campos MJ, Saad
531 WA, Pinotti HW, Zilberstein B. Chagasic megacolon and proximal jejunum microbiota.
532 Scand J Gastroenterol. v. 35, n.6, p.632-6, 2000.
- 533
534 57. Pajecki, D. et al. Megaesophagus microbiota and carcinogenesis. Arquivos de
535 Gastroenterologia, v. 40, n. 1, p. 16–19, 2003.
536
537 58. Pajecki, D. et al. Larger amounts of nitrite and nitrate-reducing bacteria in
538 megaesophagus of Chagas' disease than in controls. Journal of Gastrointestinal Surgery,
539 v. 11, n. 2, p. 199–203, 2007.
540
541 59. de Fuentes-Vicente, J. A., Gutiérrez-Cabrera, A. E., Flores-Villegas, A.
542 L.Lowenberger,C., Benelli, G., Salazar-Schettino, P. M., & Córdoba-Aguilar, A. What
543 makes an effective Chagas disease vector? Factors underlying Trypanosoma cruzi -
544 triatomine interactions. Acta Tropica, v.183, p. 23–31, 2018.
545
546 60. Husnik, F. Host-symbiont-pathogen interactions in blood-feeding parasites:
547 nutrition, immune cross-talk and gene exchange. Parasitology. v.145, n.10, 2018.
548
549 61. Kollien, A. H.; Schaub, G. A. The development of Trypanosoma cruzi in
550 triatominae. Parasitology Today, v. 16, n. 9, p. 381–387, 2000.
551
552 62. Azambuja, P.; Garcia, E. S.; Ratcliffe, N. A. Gut microbiota and parasite
553 transmission by insect vectors. Trends in Parasitology, v. 21, n. 12, p. 568–572, 2005.
554
555 63. Orantes L.C., Monroy C., Dorn P. L., Stevens L., Rizzo D. M., Morrissey L.,
556 Hanley J.P., Rodas A.G., Richards B., Wallin K. F., Helms Cahan S. Uncovering
557 vector, parasite, blood meal and microbiome patterns from mixed-DNA specimens of
558 the Chagas disease vector Triatoma dimidiata. PLoS Negl Trop Dis. v. 12, n. 10, p.
559 e0006730, 2018.
560
561 64. Mougabure-Cueto G., Picollo M. I. Insecticide resistance in vector Chagas disease:
562 evolution, mechanisms and management. Acta Trop. v. 149, p.70-85, 2015.
563
564
565 65. Saldaña, M. A.; Hegde, S.; Hughes, G. L. Microbial control of arthropod-borne
566 disease. Memórias do Instituto Oswaldo Cruz, v. 112, n. 2, p. 81–93, 2017.
567

- 568 66. Taracena M. L., Oliveira P. L., Almendares O., Umaña C., Lowenberger C., Dotson
569 E. M., Paiva-Silva G. O., Pennington P. M. Genetically modifying the insect gut
570 microbiota to control Chagas disease vectors through systemic RNAi. *PLoS Negl Trop*
571 *Dis.* v.12, e0003358, 2015.
- 572
- 573 67. Genes, C. et al. Mitochondrial dysfunction in *Trypanosoma cruzi*: The role of
574 *Serratia marcescens* prodigiosin in the alternative treatment of Chagas disease. *Parasites*
575 *and Vectors*, v. 4, n. 1, p. 66, 2011.
- 576
- 577 68. Castro, D. P. et al. Physalin B inhibits *Trypanosoma cruzi* infection in the gut of
578 *Rhodnius prolixus* by affecting the immune system and microbiota. *Journal of Insect*
579 *Physiology*, v. 58, n. 12, p. 1620–1625, 2012b.
- 580
- 581
- 582 69. Leung, J. M.; Graham, A. L.; Knowles, S. C. L. Parasite-microbiota interactions
583 with the vertebrate gut: Synthesis through an ecological lens. *Frontiers in Microbiology*,
584 v. 9, p. 1–20, 2018a.
- 585
- 586 70. Kristensen N. B., Thomas B., Kristine H. A., Trine N., Tue H. H., Oluf P.
587 Alterations in fecal microbiota composition by probiotic supplementation in healthy
588 adults: a systematic review of randomized controlled trials. *Genome Medicine*. v.8 p.52,
589 2016.
- 590
- 591
- 592 71. Bautista G.C.R., Torres Á.M.C. The inoculation of *Lactobacillus casei* in NIH mice
593 induces a protective response against *Trypanosoma cruzi* (Ninoa strain) infection. *Vet.*
594 *Méx.*, v. 39, n. 2, p.139-144, 2008.
- 595
- 596
- 597 72. Figueiredo V. P., Junior E. S. L., Lopes L. R., Simões N. F., Penitente A. R.,
598 Bearzoti E., Vieira P. M. A., Schulz R., Talvani A. High fat diet modulates
599 inflammatory parameters in the heart and liver during acute *Trypanosoma cruzi*
600 infection. *Int Immunopharmacol.* v. 64, p. 192-200, 2018.
- 601
- 602
- 603
- 604 73. Martins R. F., Martinelli P. M., Guedes P. M., da Cruz P. B., Dos Santos F. M.,
605 Silva M. E., Bahia M. T., Talvani A. Protein deficiency alters CX3CL1 and endothelin-
606 1 in experimental *Trypanosoma cruzi*-induced cardiomyopathy. *Trop Med Int Health.* v.
607 18, n. 4, p. 466-76, 2013.
- 608
- 609 74. Cintra, Isa P., Marcelo E. S., Marcílio E.C. S., Márcio E. S., L.C. C. A., Jacques R.
610 N., Eduardo A. B., Enio C. V. Influence Of Dietary Protein Content On *Trypanosoma*
611 *Cruzi* Infection In Germfree And Conventional Mice. *Rev. Inst. Med. trop. S.* v. 40 n. 6,
612 1998.
- 613 75. Santos C. F., Silva M. E., Nicoli J. R., Crocco-Afonso L. C., Santos J. E., Bambilra
614 E. A., Vieira E. C. Effect of an essential fatty acid deficient diet on experimental

615 infection with *Trypanosoma cruzi* in germfree and conventional mice. *Braz J Med Biol*
616 *Res.* v.25, n. 8, p. 795-803, 1992.

617

618 76. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper
619 DR, Bertin J, Eisenbarth SC, Gordon JI, Flavell RA. NLRP6 inflammasome regulates
620 colonic microbial ecology and risk for colitis. *Cell.* v.145, n.5, p.745-57, 2011.

621

622

623

624 77. Raymann K., Moeller A.H., Goodman A.L., Ochman H. Unexplored Archaeal
625 Diversity in the Great Ape Gut Microbiome. *mSphere.* v. 2, n. 1, p. e00026-17, 2017.

626

627

628 78. Garcia, E. S. et al. Interactions between intestinal compounds of triatomines and
629 *Trypanosoma cruzi*. *Trends in Parasitology*, v. 26, n. 10, p. 499–505, 2010.

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

Highlights

- Intestinal microbiota has a deep influence on the parasite-host relationship
- In triatomines, gut microbiota can benefit or impair *T. cruzi* survival
- In mammals, *T. cruzi*-associated dysbiosis affects immune responses
- Novel approaches based on gut microbiota can be proposed to control Chagas disease

Journal Pre-proof